The World Health Organization has reported that HIV and malaria continue to be significant public health issues around the world in 2021, with 2.3 million people living with HIV infected and 247 million malaria cases worldwide.
In response to these challenges, TransCure bioServices and The Art of Discovery are presenting a webinar to discuss the potential use of Humanized mice models in developing treatments for these infections.
In the first part, Dr. Sebastien Tabruyn, PhD, TransCure bioServices, will discuss how the human immune system responds to infection in a Humanized CD34-NCG mouse model. He will also discuss the preclinical analysis toolkit of the HIV platform, and how the Humanized mouse model allows for the evaluation of drug candidates, for infectious diseases. TransCure bioServices offers preclinical contract research services, including unique mouse modeling with functional Humanized systems, to provide predictive in vivo pharmacology testing in the field of immuno-oncology, inflammation, autoimmune diseases, infectious diseases, and vaccine development. Their unparalleled expertise, powerful Humanized mouse models, short lead times, and flexibility support clients from study design to final report.
In the second part of the webinar, Dr. Iñigo Angulo-Barturen, PhD, The Art of Discovery (TAD), will discuss the use of Humanized Plasmodium falciparum mouse models in the study of human malaria and the in vivo evaluation of new antimalarial drugs. He will present the characteristics of the Humanized P. falciparum asexual blood stage (ABS) mouse models available at TAD and how they can be used to study the development of resistance during suboptimal treatment regimens. He will also discuss the efficacy of monoclonal antibodies and drugs against susceptible and resistant strains.
Fill out the form to gain immediate access to this presentation.